Background: The COVID-19 pandemic has greatly impacted health and care workers (HCWs) globally. As front-line responders they are considered at greater risk of infection and death. This study aims to document emerging evidence on infection rates, clinical outcomes, and vaccination rates of HCWs in the months between July 2020 and June 2021. Methods: Three bibliographic databases were surveyed and resulted on 524 related-articles describing two periods of exposure between July-December 2020 (period 1) and January-June 2021 (period 2). Following a thorough quality review, 108 articles were retained in the final systematic review and meta-analysis. Results: A total of 898,203 HCWs were identified in period 1 and 82,093 HCWs in period 2, respectively. In period 1, the meta-analyses estimates were 6.1% (95% CI, 4.1 – 8.8) for the PCR positivity rate, and 7.9% (95% CI, 5.5 – 11.2) for the prevalence of seropositivity, respectively. Regarding outcomes, the estimated hospitalization prevalence was 1.6% (95% CI, 0.7-3.9), the ICU admission prevalence was 0.4% (95% CI, 0 – 3.6), and the average mortality rate was 0.3% (95% CI, 0.1 –0.8). In period 2, the estimated PCR positivity rate was 8.1% (95% CI, 4.6 – 13.8) compared with a seropositivity rate of 7.4% (95% CI, 5.3-10.3). Analysis of HCWs outcomes during period 2 reveal an estimated hospitalization rate of 0.7% (95% CI 0.3-1.8), an ICU admission rate of 0.2% (95% CI, 0.0-2.8), and an average mortality rate of 0.3% (95% CI 0.1-0.9), respectively.The available evidence on HCWs vaccination rates was limited and variable yet positively indicating that about 6 in ten HCWs were vaccinated (59.0%, 95 CI, 39.4-76.1). Conclusion: Compared with the earlier half of 2020, our analysis affirm a declining trend of PCR positivity among HCWs, as well as improved clinical outcomes in the one-year period of exposure (mid 2020-mid 2021). These results correlate well with the improving uptake of COVID-19 vaccination globally. As the pandemic continues into its third year, observational studies and surveillance data remain a priority investment to monitor COVID-19 infections and outcomes affecting HCWs vis-a-vis the protective effects expected by vaccination uptake. Funding: None to declare. Declaration of Interest: None to declare.